A decade of leadership in inflammatory bowel disease, and we’re not done yet. We’re innovating and investing to serve patients in two ways: 1. developing options for how they administer their medicines (intravenous vs. subcutaneous); and 2. maintaining continuity in our manufacturing capacity and a resilient supply chain to make the medicines they need. Our strategy includes major investments in our Linz, Austria, and Hikari, Japan, manufacturing sites, where we’ve extended our company’s 243-year legacy of innovation to address patient needs. #IBD
